Atrium Therapeutics Reports Q3 2026 Results, $293.6 Million Pro Forma Cash

Atrium Therapeutics reported third-quarter 2026 collaboration revenue of $15.3 million and a net loss of $4.3 million. The company ended September with $232.1 million in cash, cash equivalents and short-term investments; including a subsequent milestone payment and private placement, pro forma cash…